Forecast
Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional
Food and Drug Administration
AI Overview
This FDA funding opportunity seeks development of physiologically-based pharmacokinetic (PBPK) modeling and mechanistic in vitro-in vivo correlation (IVIVC) approaches for long-acting injectable suspensions and implants. The research aims to improve drug development efficiency and regulatory decision-making for complex formulations.
This summary is AI-generated from the official solicitation.
Key Details
Agency
Food and Drug Administration
Funding Amount
—
Release Date
November 21, 2023
Due Date
—
Similar Opportunities
Forecast
AJ13--Pharmarcokinetics for Experimental Rheumatoid Arthritis treatment
Due July 31, 2026
ForecastAJ13--Liposome Preparation for Experimental Rheumatoid Arthritis treatment
Due July 31, 2026
ActiveGenerative Unconstrained Intelligence Drug Engineering (GUIDE) collaboration between U.S. interagency, academic and industry partners
Due October 18, 2028
Get Alerts for Opportunities Like This
RallyProp monitors thousands of funding sources and sends instant alerts when opportunities match your technology and capabilities.
Start Free Trial